株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

関節リウマチ(RA)

Digital Landscape: Rheumatoid Arthritis

発行 GlobalData 商品コード 692906
出版日 ページ情報 英文 162 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.05円で換算しております。
Back to Top
関節リウマチ(RA) Digital Landscape: Rheumatoid Arthritis
出版日: 2018年09月03日 ページ情報: 英文 162 Pages
概要

当レポートでは、米国およびEUCAN諸国(EU5カ国・カナダ)の製薬企業がデジタル環境(ブランドウェブサイト、非ブランド/疾患啓発ウェブサイト、モバイルアプリ、ソーシャルメディア)で関節リウマチ患者および医療従事者を対象に展開している取り組みについて詳細に調査し、主要企業の動向の比較、ウェブサイトアクセス数やアプリダウンロード数などのデータ分析、新たなキャンペーン活動の機会の特定、デジタルヘルスを形作るトレンドの評価、患者および医師のオンライン利用実態などについてまとめています。

対象企業

AbbVie、Janssen、Pfizer、Roche、Genentech、Chugai、BMS、Sanofi、Genzyme、Regeneron、Amgen、UCB、MSD、Merck、Eli Lilly、Sandoz、Biogen

目次

  • エグゼクティブサマリー
  • 近年の動向
  • 情勢と分析
  • 米国:関節リウマチ患者を対象とした取り組み
  • 米国:医療従事者を対象とした取り組み
  • EUCAN諸国:関節リウマチ患者を対象とした取り組み
  • EUCAN諸国:医療従事者を対象とした取り組み
  • 調査手法
目次
Product Code: GDHC042SP

"Digital Landscape: Rheumatoid Arthritis", analyzes digital activities undertaken by pharma in support of therapies for moderate-to-severe rheumatoid arthritis (RA).

The report includes digital activities directed towards patients and/or HCPs.

The geographic scope of the report is the United States, EUCAN (Canada and the 5EU countries - UK, Germany, France, Italy & Spain).

Key Highlights

  • US Patients: AbbVie offers the strongest support for RA patients in the US, particularly branded, unbranded and mobile app. Branded activity seen from Janssen with its counter-biosimilar campaign for Remicade, while new advertising campaigns seen for Enbrel and Xeljanz. Sanofi entered the space for the first time following approval of Kevzara. Opportunity exists for a well-integrated unbranded campaign to support patients, linked to social media and a mobile app.
  • US HCPs: Good branded support available for US HCPs in the RA space. Sanofi launched a HCP site for Kevzara, supported by high paid advertising spend. Branded activity also detected from AbbVie, BMS, as well as biosimilar manufacturer Pfizer. Unbranded and mobile app landscapes are sparse. Opportunities may exist to develop or sponsor content with trusted non-pharma organizations. Social media activity restricted to corporate accounts.
  • EUCAN Patients: Good branded support is available for RA patients in Germany, the UK, and Canada. No multi-country, local-language unbranded campaigns detected, with good examples of local sites seen, and support strongest from Roche / Chugai overall. Social media support limited to country-specific pages in Spain and France, RA patients have access to good mobile app offerings, however none detected in Spain or Italy.
  • EUCAN HCPs: The EUCAN HCP landscape is underdeveloped, with little activity seen past branded. New brand activity seen for Xeljanz and Olumiant. The unbranded and mobile app landscapes are particularly sparse, and partnerships with non-pharma organizations may offer more effective opportunities to engage with and support HCPs.
  • Companies Mentioned, AbbVie, Janssen, Pfizer, Roche / Genentech / Chugai, BMS, Sanofi Genzyme / Regeneron, Amgen, UCB, MSD / Merck, Eli Lilly, Sandoz, Biogen.

Scope

  • This report analyzes digital activities undertaken by pharma in support of therapies for therapies for moderate-to-severe rheumatoid arthritis (RA).
  • The report includes digital activities directed towards patients and/or HCPs, including branded websites, unbranded disease awareness initiatives, social media and mobile apps.
  • The report is based on analysis conducted by a combination of GlobalData's digital and disease-specific teams. It also includes analysis of data licensed from third parties e.g. website traffic, search engine optimization (SEO), digital display advertising, mobile app downloads, and social media interaction.
  • The geographic scope of the report is the United States, Canada and the 5EU (UK, Germany, France, Italy & Spain), with EUCAN used as an abbreviation for Europe and Canada throughout.
  • This report covers the research period from January - December 2017.

Reasons to buy

  • Our Digital Landscape report provides an analysis of pharma multichannel activity in the digital RA space, and can assist our pharma clients derive value in a number of ways:
  • Competitive Intelligence: Track and compare key competitor activity across channels and identify key trends in RA
  • Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns
  • Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands
  • Business Development & Licensing: Assess topics and trends shaping digital health in RA and beyond, and learn about key patient and physician online activities in RA.

Table of Contents

  • Executive Summary
  • Recent Developments
  • Landscape & Analysis
  • US: Patient-directed Activities
  • US HCP-directed Activities
  • EUCAN Patient-directed Activities
  • EUCAN HCP-directed Activities
  • Methodology
Back to Top